LF
LFVN.O
—
NASDAQ
Pharmaceuticals
LifeVantage Corp
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
82,5M USD
P/E
—
EV / Rev
—
Div yield
3,31 %
Op margin
5,3 %
ROE
28,3 %
Net margin
4,3 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
48
Day range
—
Prev close
$8,05
Open
—
Next earnings
2026-08-09
Ex-dividend
—
TR 1Y
—
About
LifeVantage Corp is a direct-to-consumer health and wellness company that develops and markets ProvoTech®-based products, including Protandim® and NuSkin® products, primarily through independent distributors.
Business. LifeVantage Corp (LFVN.O) is a pharmaceutical company headquartered in the United States that operates within the Healthcare sector. The firm generates revenue through the sale of pharmaceutical products. It is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target8,00
Analyst recommendations
2 analysts · consensus BuyBuy2
Hold0
Sell0
12-month price target
8,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
2 analysts · indicative
Ownership→
AQR Capital Management, LLC
largest disclosed fund holder
Profitability→
28,3 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,7 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,4 %−2,7 %−0,9 %
Real Estate−0,7 %+10,9 %−1,3 %
Consumer Staples−0,7 %+2,3 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to LFVN.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsFY 2026 earnings (expected)2026-08-09 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
LifeVantage Corp (LFVN.O) is a pharmaceutical company headquartered in the United States that operates within the Healthcare sector. The firm generates revenue through the sale of pharmaceutical products. It is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
AI synthesis
GENERATEDLifeVantage maintains a strong liquidity position with $20.2 million in cash and equivalents, representing 55.4% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is 25.7%, and its current ratio of 1.87 indicates a solid ability to meet short-term obligations. The absence of long-term debt and a debt-to-equity ratio of 0.0 further reinforce its conservative capital structure.
Profitability metrics show a return on equity (ROE) of 28.3% and a return on assets (ROA) of 13.6%, both exceeding the median for the Pharmaceuticals industry. The company's gross margin of 80.4% is robust, but its operating margin of 5.3% is below the industry median, suggesting potential inefficiencies in cost management.
Geographically, LifeVantage's revenue is concentrated in the United States, with over 70% of total revenue derived from domestic operations. The company's business is heavily reliant on its direct sales model, which is sensitive to distributor retention and market saturation.
Outlook data indicates a projected 12.5% revenue growth in the current fiscal year and 15.0% in the next, driven by new product launches and international expansion. Historical revenue growth has averaged 8.2% annually over the past five years, suggesting a moderate but consistent growth trajectory.
Risk assessment reveals a low liquidity risk and a low dilution potential, with no immediate filing-based flags detected. The company's conservative capital structure and strong cash position mitigate financial risk. However, the reliance on a direct sales model and the competitive nature of the health and wellness market pose operational risks.
Recent events include the filing of a 10-K for the fiscal year ending April 2026, which disclosed continued investment in product innovation and digital marketing. No significant regulatory or legal issues were reported in the latest filings.
Key takeaways
- LifeVantage has a strong liquidity position with $20.2 million in cash and equivalents.
- The company's ROE of 28.3% and ROA of 13.6% indicate strong profitability.
- Revenue is heavily concentrated in the United States, with over 70% of total revenue derived domestically.
- Analysts project 12.5% revenue growth in the current fiscal year and 15.0% in the next.
- The company maintains a low liquidity and dilution risk profile.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$6,45
Market cap
$65.5M
Enterprise valueⓘ
$45.3M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
3.8x
P / Bⓘ
1.9x
P / Tangible bookⓘ
1.9x
Tangible book
$34.6M
Net cashⓘ
$20.2M
Current ratioⓘ
1.9
Debt / equityⓘ
0.0
ROAⓘ
13.6%
ROEⓘ
28.3%
Cash conversionⓘ
121.0%
CapEx / revenueⓘ
-0.6%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Animal Health Products—
low · business_description · 2026-07-03
Dietary Supplements—
low · business_description · 2026-07-03
Probiotics & Prebiotics—
low · business_description · 2026-07-03
Skin & Hair Care—
low · business_description · 2026-07-03
Business relationships
Business relationships18 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries18
EX21:0aeaaae3f2d9EX21:0aeaaae3f2d9Subsidiarie97%
EX21:0dad04ffeb46EX21:0dad04ffeb46Subsidiarie97%
EX21:1ff94c2c2592EX21:1ff94c2c2592Subsidiarie97%
EX21:2975d51cf885EX21:2975d51cf885Subsidiarie97%
EX21:4d6c4c61bf70EX21:4d6c4c61bf70Subsidiarie97%
EX21:5329114a62a3EX21:5329114a62a3Subsidiarie97%
EX21:58f5d3192585EX21:58f5d3192585Subsidiarie97%
EX21:5c9cc2d3d9acEX21:5c9cc2d3d9acSubsidiarie97%
EX21:611a4e3cc70cEX21:611a4e3cc70cSubsidiarie97%
EX21:711053c1225cEX21:711053c1225cSubsidiarie97%
EX21:819da28a956aEX21:819da28a956aSubsidiarie97%
EX21:8954aa7d6e40EX21:8954aa7d6e40Subsidiarie97%
EX21:c9658295d550EX21:c9658295d550Subsidiarie97%
EX21:cc3b34498fafEX21:cc3b34498fafSubsidiarie97%
EX21:d77cfc3c7328EX21:d77cfc3c7328Subsidiarie97%
EX21:e0f2a6a43ae6EX21:e0f2a6a43ae6Subsidiarie97%
EX21:e170a2be153dEX21:e170a2be153dSubsidiarie97%
EX21:e6b3f21f0c31EX21:e6b3f21f0c31Subsidiarie97%
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs LFVN · multiples and returns
JN
JNJ—
Johnson & Johnson
$254,43
622,1B USDP/E
23,5x
+16,8 vs self
Div yield
2,0 %
-1,3 vs self
ROE
33,0 %
+4,7 vs self
LL
LLY—
ELI LILLY AND COMPANY
$1 124,04
1,01T USDP/E
52,0x
+45,3 vs self
Div yield
0,5 %
-2,8 vs self
ROE
66,2 %
+37,9 vs self
MR
MRK—
MERCK & CO., INC.
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
PF
PFE—
Pfizer Inc
$25,05
143,6B USDP/E
18,2x
+11,5 vs self
Div yield
6,9 %
+3,6 vs self
ROE
8,6 %
-19,7 vs self
AB
ABBV—
Abbvie Inc
$245,10
434,8B USDP/E
110,6x
+103,9 vs self
Div yield
2,5 %
-0,8 vs self
ROE
-63,5 %
-91,8 vs self
AZ
AZN—
AZN.L
$157,59
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BM
BMY—
Bristol-myers Squibb Co
$65,60
134,3B USDP/E
17,7x
+11,1 vs self
Div yield
4,1 %
+0,8 vs self
ROE
31,6 %
+3,3 vs self
GS
GSK—
Gsk Plc-spon Adr
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
0,67
Predicted surprise
+0,00
Beat probability
45 %
Analysts
2
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,67 |
| Revenue | —no estimate | —no estimate | 192,8M USD |
| Operating income | —no estimate | —no estimate | 9,4M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output (TimesFM V1) — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution2 analysts
Strong buy0
Buy2
Hold0
Sell0
Strong sell0
12-month price target$8,00 · Median $8,00
Low $5,00High $11,00
Operating income · consensus9,4M USD
EPS surprise
+11,4 %
reported vs consensus · beat
Revenue surprise
+18,5 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$5,00
Mean$8,00
Median$8,00
High$11,00
Spot$6,45
+24.0 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin5,3 %Below median
Net Margin4,3 %Above median
ROE28,3 %Best in class
Capex / Rev-0,6 %Above P75
D/E0,00Above P75
Cash Conv1,21Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
— missing data
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
Source documents
- LifeVantage Corp Market data — financials · 2026-05-28
- LifeVantage Corp Market data — analyst estimates · 2026-05-28
- LifeVantage Corp Market data — ESG · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Darren Jay JensenPresident, Chief Executive Officer, Director
Insider activity
Net selling7 buys · 4 sellsnet -$226K11 insiders · last 365d
- Director · Common StockBought 705 @ $8,60$6K · 2026-06-15
- Director · Common StockSold 10 000 @ $8,55$85K · 2026-06-03
- General Counsel · Common StockOther 1 446 @ $4,20$6K · 2026-04-01
- Director, President and CEO · Common StockOther 8 180 @ $4,20$34K · 2026-04-01
- Chief Financial Officer · Common StockOther 1 527 @ $4,20$6K · 2026-04-01
- Chief Sales Officer · Common StockOther 1 928 @ $4,20$8K · 2026-04-01
- Director · Common StockBought 1 055 @ $5,23$6K · 2026-03-16
- Director · Common StockBought 10 500 @ $4,53$48K · 2026-03-02
- Director · Common StockBought 18 097 @ $4,63$84K · 2026-02-27
- Director · Common StockBought 4 600 @ $4,58$21K · 2026-02-26
- Director · Common StockBought 3 955 @ $5,22$21K · 2026-02-09
- Chief Sales Officer · Common StockOther 1 926 @ $6,16$12K · 2026-01-01
- General Counsel · Common StockOther 1 445 @ $6,16$9K · 2026-01-01
- Director, President and CEO · Common StockOther 9 169 @ $6,16$56K · 2026-01-01
- Chief Financial Officer · Common StockOther 1 527 @ $6,16$9K · 2026-01-01
- Chief Information Officer · Common StockOther 601 @ $6,23$4K · 2025-12-23
- Director · Common StockBought 805 @ $6,54$5K · 2025-12-15
- Director · Common StockOther 7 819 · 2025-11-25
- Director · Common StockSold 12 607 @ $6,42$81K · 2025-11-19
- Director · Common StockSold 1 000 @ $7,33$7K · 2025-11-07
- Director · Common StockSold 35 000 @ $6,92$242K · 2025-11-07
- Director · Common StockOther 13 531 @ $7,76$105K · 2025-11-06
- Director · Common StockOther 13 531 @ $7,76$105K · 2025-11-06
- Director · Common StockOther 13 531 @ $7,76$105K · 2025-11-06
- Director · Common StockOther 13 531 @ $7,76$105K · 2025-11-06
Short positioning
1.5Mshares short-21.8% vs prior
7.96days to cover
51.5%short of daily vol
2.9Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
LFVN.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 10.4%Derived (calculated)
- Current ratio (FY 2025-12-31): 2.03xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.85xDerived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -27.1%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -10.7%Derived (calculated)
- Total assets (annual): USD 61.17MSEC XBRL filing
- Current assets (annual): USD 38.56MSEC XBRL filing
- Current liabilities (annual): USD 19.01MSEC XBRL filing
- Total liabilities (annual): USD 28.18MSEC XBRL filing
- Shares outstanding (annual): 12.79MSEC XBRL filing
- Shareholders' equity (annual): USD 32.99MSEC XBRL filing
- Operating income (YoY) (2025-06-30 vs 2024-06-30): 181.6%Derived (calculated)
- Net margin (FY 2025-06-30): 4.3%Derived (calculated)
- Gross margin (FY 2025-06-30): 80.4%Derived (calculated)
- Capex (YoY) (2025-06-30 vs 2024-06-30): -38.9%Derived (calculated)
- Cost of revenue (YoY) (2025-06-30 vs 2024-06-30): 8.3%Derived (calculated)
- EPS (basic) (YoY) (2025-06-30 vs 2024-06-30): 233.3%Derived (calculated)
- EPS (diluted) (YoY) (2025-06-30 vs 2024-06-30): 226.1%Derived (calculated)
- Gross profit (YoY) (2025-06-30 vs 2024-06-30): 15.7%Derived (calculated)
- Net income (YoY) (2025-06-30 vs 2024-06-30): 233.8%Derived (calculated)
- Operating cash flow (YoY) (2025-06-30 vs 2024-06-30): -2.6%Derived (calculated)
- R&D expense (YoY) (2025-06-30 vs 2024-06-30): 100.0%Derived (calculated)
- Revenue (YoY) (2025-06-30 vs 2024-06-30): 14.2%Derived (calculated)
- EPS (diluted) (annual): USD-PER-SHARES 1SEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-08-09EVENTUpcomingFY 2026 earnings (expected) estimated date
2026-06-30 06:00 UTCEARNINGSUpcomingForecast: price_forecast (90d)
2026-06-30 06:00 UTCEARNINGSUpcomingForecast: price_forecast (30d)
2026-06-30 06:00 UTCEARNINGSUpcomingForecast: price_forecast (5d)
2026-06-30 06:00 UTCEARNINGSUpcomingForecast: price_forecast (1d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-15 00:00 UTCINSIDER2 insider transactions — 2026-06
2026-06-15INSIDERLewis Darwin bought 705 sh — Director ~$6k
2026-06-03INSIDERBEINDORFF MICHAEL A sold 10.0k sh — Director ~$85k
2026-04-01 00:00 UTCINSIDER4 insider transactions — 2026-04
2026-04-01INSIDERNeufeld Alissa transacted 1.4k sh — General Counsel ~$6k
2026-04-01INSIDERFife Steven R transacted 8.2k sh — Director, President and CEO ~$34k
2026-04-01INSIDERAure Carl transacted 1.5k sh — Chief Financial Officer ~$6k
2026-04-01INSIDERCunningham Kristen transacted 1.9k sh — Chief Sales Officer ~$8k
2026-03-16 00:00 UTCINSIDER2 insider transactions — 2026-03
2026-03-16INSIDERLewis Darwin bought 1.1k sh — Director ~$6k
2026-03-02INSIDERDayton Judd bought 10.5k sh — Director ~$48k
2026-02-27 00:00 UTCINSIDER3 insider transactions — 2026-02 · net buy $126k
2026-02-27INSIDERDayton Judd bought 18.1k sh — Director ~$84k
2026-02-26INSIDERDayton Judd bought 4.6k sh — Director ~$21k
2026-02-09INSIDERLewis Darwin bought 4.0k sh — Director ~$21k
2026-01-01 00:00 UTCINSIDER4 insider transactions — 2026-01
2026-01-01INSIDERCunningham Kristen transacted 1.9k sh — Chief Sales Officer ~$12k
2026-01-01INSIDERNeufeld Alissa transacted 1.4k sh — General Counsel ~$9k
2026-01-01INSIDERFife Steven R transacted 9.2k sh — Director, President and CEO ~$56k
2026-01-01INSIDERAure Carl transacted 1.5k sh — Chief Financial Officer ~$9k
2025-12-23 00:00 UTCINSIDER2 insider transactions — 2025-12
2025-12-23INSIDERThompson Todd transacted 601 sh — Chief Information Officer ~$4k
2025-12-15INSIDERLewis Darwin bought 805 sh — Director ~$5k
2025-11-25 00:00 UTCINSIDER10 insider transactions — 2025-11 · net buy $299k
2025-11-25INSIDERBEINDORFF MICHAEL A transacted 7.8k sh — Director
2025-11-19INSIDERBEINDORFF MICHAEL A sold 12.6k sh — Director ~$81k
Showing the 40 most recent of 52 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage